2024 saw the establishment of docetaxel, oxaliplatin, leucovorin, and 5-fluorouracil as the preferred regimen for patients ...

Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Squamous Cell Carcinoma.

Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase III for Peritoneal Cancer.

More research is needed to refine treatment strategies and identify predictive biomarkers for patient selection, according to researchers.

Tevimbra is already approved in the US for the treatment of unresectable or metastatic oesophageal squamous cell carcinoma ...

Beijing will impose visa restrictions on “US personnel who have behaved poorly on Hong Kong-related issues” in response to Washington’s threats to sanction officials responsible for ...

During a Case-Based Roundtable® event, David H. Ilson, MD, PhD, discussed the outcomes of the CheckMate 649, CheckMate 648, ...

PHOENIX -- Pollster Mike Noble says he knows why Democrats in Arizona generally did so poorly in the last election ... Noble said there's nothing inconsistent about that. He said voters differentiated ...

Randomized Phase 2 study initiated evaluating the combination of casdozokitug, toripalimab and bevacizumab in patients with liver cancer - REDWOOD CITY, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- ...

This would have been eye-opening for the Dutchman as to what can happen when one of the weaker squads is missing a handful of starters and performs poorly. Even against an out-of-form mid-table ...

The pathological examination of the biopsied specimen indicated a poorly differentiated adenocarcinoma. Immunohistochemistry was negative for Her2neu, positive for programmed cell death ligand one ...